ArticleJournal of Cancer2019
Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA.
Open access · goldAbstract read
In one paragraph
Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 58 citations in OpenAlex.
- Advancing the Diagnosis of Non-Hodgkin Lymphoma Through Next-Generation Sequencing in Developing Countries: An Evaluation of Progress-A Narrative Review.Health science reports · 2026Article
- The prognostic and clinical utility of circulating tumor DNA in diffuse large B-cell lymphoma: a systematic review and meta-analysis.NPJ precision oncology · 2025Review
- Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside.International journal of molecular sciences · 2025Review
- An Investigation into Cell-Free DNA in Different Common Cancers.Molecular biotechnology · 2024Review
- Imaging Flow Cytometry: Development, Present Applications, and Future Challenges.Methods and protocols · 2024Review
- Emerging ctDNA detection strategies in clinical cancer theranostics.Smart medicine · 2023Review
- Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- The implication of next-generation sequencing in the diagnosis and clinical management of non-Hodgkin lymphomas.Frontiers in oncology · 2023Review
- The Value of Cell-Free Circulating DNA Profiling in Patients with Skin Diseases.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Circulating Tumor DNA Profiling of a Diffuse Large B Cell Lymphoma Patient with Secondary Acute Myeloid Leukemia.Cancers · 2022Article
- Article
- Tumor mutation burden determined by a 645-cancer gene panel and compared with microsatellite instability and mismatch repair genes in colorectal cancer.Journal of gastrointestinal oncology · 2021Article
- Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Review
- Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology?Molecular diagnosis & therapy · 2021Review
- Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring.Blood advances · 2021Article
- Review
- Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma.Experimental hematology & oncology · 2021Article
- High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.Current hematologic malignancy reports · 2021Review
- Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma.Frontiers in oncology · 2021Review
- Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients.Cancer medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Peng SunState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng RD East, Guangzhou, Guangdong Province 510060, P. R. China.
Cui ChenDepartment of Oncology, the First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Road II, Guangzhou, Guangdong Province 510080, P. R. China.
Yi XiaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng RD East, Guangzhou, Guangdong Province 510060, P. R. China.
Yu WangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng RD East, Guangzhou, Guangdong Province 510060, P. R. China.
Pan-Pan LiuState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng RD East, Guangzhou, Guangdong Province 510060, P. R. China.
Xi-Wen BiState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng RD East, Guangzhou, Guangdong Province 510060, P. R. China.
Yang W ShaoGeneseeq Technology Inc., 101 College Street, Suite 300, Toronto, Ontario, Canada.
Qiu-Xiang OuGeneseeq Technology Inc., 101 College Street, Suite 300, Toronto, Ontario, Canada.
Xue WuGeneseeq Technology Inc., 101 College Street, Suite 300, Toronto, Ontario, Canada.
Hang YangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng RD East, Guangzhou, Guangdong Province 510060, P. R. China.
Man NieState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng RD East, Guangzhou, Guangdong Province 510060, P. R. China.
Xue-Wen ZhangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng RD East, Guangzhou, Guangdong Province 510060, P. R. China.
Zhi-Ming LiState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng RD East, Guangzhou, Guangdong Province 510060, P. R. China.
Wen-Qi JiangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng RD East, Guangzhou, Guangdong Province 510060, P. R. China.
Sun Yat-sen University · CNSUNY Geneseo · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Chinacirculating cell-free DNAmalignant lymphomanext-generation sequencing (NGS)tumor heterogeneity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.